ABUS
Arbutus Biopharma Corp
Arbutus Biopharma Corp
$ABUS reports Positive Clinical Data for HBV-focused Therapeutic and Robust Financial Position for Q1 2023
Arbutus Biopharma has reported positive data from its RNAi therapeutic, AB-729, for Hepatitis B virus, including low levels of HBsAg and HBV DNA in patients for over a year and a half after their last dose. The biopharmaceutical company also dosed the first healthy subject in its Phase 1 trial for AB-161, an oral RNA destabilizer, with data expected later this year; as well as advancing its coronavirus programs. While the company's financial situation is stable, with cash of $178.3m till Q1 2025, the Q1 2023 net loss of $27.1m was attributed to trial discontinuation and expenses for coronavirus and early-stage programs.
4mo ago
$ABUS